Accelerating IMPT-314 in large B-cell lymphoma; remain on track to initiate pivotal trial in the 3rd line+ setting in 2025 ...

On Astellas Pharma’s mission to develop new cell therapies in cancers and other diseases, not all candidates are destined to ...

These ASX All Ords shares have soared 16% to 37% already in 2025. The post 3 ASX All Ords shares leading the charge in 2025 ...

The National Comprehensive Cancer Network® (NCCN®)?a global not-for-profit alliance of leading cancer centers?is taking part in a two-day meeting at the Middle East North Africa (MENA)-NCCN Regional ...

PatientPoint®, the trusted leader at improving patient health outcomes at key points of change in and around ...

Nurix Therapeutics (NRIX) leads in targeted protein modulation with its DELigase platform, developing BTK degraders like ...

Geode Capital Management LLC lifted its position in shares of Adicet Bio, Inc. (NASDAQ:ACET – Free Report) by 14.5% in the third quarter, Holdings Channel reports. The institutional investor owned 768 ...

Thanks to an innovative method of super-resolution microscopy, researchers from the University of Würzburg have observed ...

In fact, from Merck's $1.3 billion deal to GSK's $850 million investment, the "gold content" of Chinese companies' self-developed TCE bispecific antibodies has already been well proven. The new moves ...

Würzburg researchers show in the journal 'Science' how therapeutic antibodies work - thanks to an innovative method of ...

Vantage Markets, a leading multi-asset trading platform, is set to make a significant impact at the upcoming iFX EXPO Dubai ...

Stock analysts at Brookline Capital Management issued their FY2029 earnings estimates for shares of Caribou Biosciences in a ...